David M. Epstein's most recent trade in Gyre Therapeutics Inc was a trade of 26,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 4, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Gyre Therapeutics Inc | David M. Epstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2025 | 26,000 | 26,000 | - | - | Stock Option (Right to Buy) | |
| Gyre Therapeutics Inc | David M. Epstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2024 | 52,000 | 52,000 | - | - | Stock Option (Right to Buy) | |
| Gyre Therapeutics Inc | David M. Epstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2024 | 1,866 | 1,866 | - | - | Stock Option (Right to Buy) | |
| Black Diamond Therapeutics Inc | David M. Epstein | Director, SEE REMARKS | Sale of securities on an exchange or to another person at price $ 6.70 per share. | 27 Jun 2023 | 25,000 | 671,423 (1%) | 0% | 6.7 | 167,500 | Common Stock |
| Black Diamond Therapeutics Inc | David M. Epstein | Director, SEE REMARKS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 420,000 | 420,000 | - | - | Stock Option (Right to Buy) | |
| Black Diamond Therapeutics Inc | David M. Epstein | Director, SEE REMARKS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 300,000 | 300,000 | - | - | Stock Option (Right to Buy) | |
| Black Diamond Therapeutics Inc | David M. Epstein | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2021 | 225,000 | 225,000 | - | - | Stock Option (Right to Buy) | |
| Black Diamond Therapeutics Inc | David M. Epstein | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 30.99 per share. | 04 Jan 2021 | 9,985 | 698,438 (1%) | 0% | 31.0 | 309,430 | Common Stock |
| Black Diamond Therapeutics Inc | David M. Epstein | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.42 per share. | 04 Jan 2021 | 3,000 | 708,423 (1%) | 0% | 6.4 | 19,260 | Common Stock |
| Black Diamond Therapeutics Inc | David M. Epstein | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2021 | 3,000 | 230,116 | - | - | Stock Option (Right to Buy) | |
| Black Diamond Therapeutics Inc | David M. Epstein | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 31.80 per share. | 04 Jan 2021 | 2,015 | 696,423 (1%) | 0% | 31.8 | 64,075 | Common Stock |
| Black Diamond Therapeutics Inc | David M. Epstein | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.42 per share. | 15 Dec 2020 | 2,500 | 705,423 (1%) | 0% | 6.4 | 16,050 | Common Stock |
| Black Diamond Therapeutics Inc | David M. Epstein | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2020 | 2,500 | 233,116 | - | - | Stock Option (Right to Buy) |